Submission of intimation of preferential issue of equity shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories' board, on October 9, 2025, approved issuing 3,04,58,187 equity shares at Rs. 91 each (face value Rs. 10 + premium of Rs. 81), aggregating to about Rs. 277.17 crore. These shares will be allotted to 135 shareholders of Sriven Pharmachem India Private Limited as consideration other than cash, i.e. in exchange for acquiring 100% of Sriven Pharmachem's equity. This is a share-swap (stock-for-stock) acquisition, not a cash deal, and is routed through a preferential allotment under SEBI ICDR regulations. The issue is subject to shareholder approval at an Extra-Ordinary General Meeting and other regulatory clearances.
Existing shareholders of Astal Laboratories will face significant dilution as over 3 crore new shares (at Rs. 91) will be issued, expanding the equity base materially. The deal is non-cash, so it does not strain liquidity, but success depends on Sriven Pharmachem turning out to be a value-accretive acquisition; the share price could react once the swap ratio and target's financials are assessed.